Patents by Inventor A. Edward Osawa

A. Edward Osawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8512729
    Abstract: Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like.
    Type: Grant
    Filed: October 31, 2012
    Date of Patent: August 20, 2013
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Donald G. Wallace, Cary J. Reich, Narinder S. Shargill, Felix Vega, A. Edward Osawa, Zhen Qian-Wallis
  • Patent number: 8383141
    Abstract: Dry cross-linked gelatin compositions are prepared that rapidly re-hydrate to produce gelatin hydrogels suitable as hemostatic sealants. Gelatin is cross-linked in the presence of certain re-hydration aids, such as polyethylene glycol, polyvinylprovidone, and dextran, in order to produce a dry cross-linked gelatin powder. The use of the re-hydration aids has been found to substantially increase the re-hydration rate in the presence of an aqueous re-hydration medium, typically thrombin-containing saline.
    Type: Grant
    Filed: July 21, 2008
    Date of Patent: February 26, 2013
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Zhen Qian, A. Edward Osawa, Cary J. Reich
  • Patent number: 8357378
    Abstract: Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like.
    Type: Grant
    Filed: May 24, 2011
    Date of Patent: January 22, 2013
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Donald G. Wallace, Cary J. Reich, Narinder S. Shargill, Felix Vega, A. Edward Osawa
  • Patent number: 8303981
    Abstract: Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like.
    Type: Grant
    Filed: July 1, 2011
    Date of Patent: November 6, 2012
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Donald G. Wallace, Cary J. Reich, Narinder S. Shargill, Felix Vega, A. Edward Osawa, Zhen Qian-Wallis
  • Publication number: 20120207813
    Abstract: Compositions, methods, and kits are provided for sealing applications. Compositions are prepared by combining a first cross-linkable component with a second cross-linkable component to form a porous matrix having interstices, and combining the porous matrix with a hydrogel-forming component to fill at least some of the interstices. The compositions exhibit minimal swelling properties.
    Type: Application
    Filed: April 26, 2012
    Publication date: August 16, 2012
    Applicants: Baxter Healthcare S.A., Baxter International Inc.
    Inventors: Woonza M. RHEE, Cary J. REICH, A. Edward OSAWA, Felix VEGA
  • Publication number: 20120134980
    Abstract: Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like.
    Type: Application
    Filed: July 1, 2011
    Publication date: May 31, 2012
    Applicants: Baxter Healthcare S.A., Baxter International Inc.
    Inventors: Donald G. Wallace, Cary J. Reich, Narinder S. Shargill, Felix Vega, A. Edward Osawa, Zhen Qian-Wallis
  • Publication number: 20120128653
    Abstract: Described is a process for making a dry and stable hemostatic composition, said process comprising a) providing a first component comprising a dry preparation of a coagulation inducing agent, b) providing a second component comprising a dry preparation of a biocompatible polymer suitable for use in hemostasis, c) mixing said first component and said second component under conditions effective to form a wet paste while essentially preventing degradation of the second component by said first component in a final container or transferring said wet paste into a final container, d) freezing and lyophilizing said paste in said container thereby obtaining a dry and stable hemostatic composition comprising said first and said second component in lyophilized form, and e) finishing said dry and stable hemostatic composition in said final container to a storable pharmaceutical device containing said first component and said second component in a combined form as a dry and stable hemostatic composition.
    Type: Application
    Filed: June 1, 2011
    Publication date: May 24, 2012
    Applicants: Baxter Healthcare S.A., Baxter International Inc.
    Inventors: Andreas Goessl, Atsushi Edward Osawa, Cary J. Reich
  • Publication number: 20120121532
    Abstract: Described is a process for making a dry and stable hemostatic composition, said process comprising a) providing a first component comprising a dry preparation of a coagulation inducing agent, b) providing a second component comprising a dry preparation of a biocompatible polymer suitable for use in hemostasis, c) providing said first component and said second component in a combined form in a final container, c1) either by filling said first component and said second component into said final container so as to obtain a dry mixture in said final container, c2) or by providing said first component or said second component in said final container and adding said second component or said first component so as to obtain a combination of said first component with said second component in said final container, d) finishing the final container to. a storable pharmaceutical device containing said first component and said second component in a combined form as a dry and stable hemostatic composition.
    Type: Application
    Filed: June 1, 2011
    Publication date: May 17, 2012
    Applicants: Baxter Healthcare S.A., Baxter International Inc.
    Inventors: Andreas Goessl, Atsushi Edward Osawa, Cary J. Reich
  • Patent number: 8092820
    Abstract: Dry cross-linked gelatin compositions are prepared that rapidly re-hydrate to produce gelatin hydrogels suitable as hemostatic sealants. Gelatin is cross-linked in the presence of certain re-hydration aids, such as polyethylene glycol, polyvinylprovidone, and dextran, in order to produce a dry cross-linked gelatin powder. The use of the re-hydration aids has been found to substantially increase the re-hydration rate in the presence of an aqueous re-hydration medium, typically thrombin-containing saline.
    Type: Grant
    Filed: May 19, 2009
    Date of Patent: January 10, 2012
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Zhen Qian, A. Edward Osawa, Cary J. Reich
  • Publication number: 20110223231
    Abstract: Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like.
    Type: Application
    Filed: May 24, 2011
    Publication date: September 15, 2011
    Applicants: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Donald G. Wallace, Cary J. Reich, Narinder S. Shargill, Felix Vega, A. Edward Osawa
  • Publication number: 20110202026
    Abstract: The present invention provides a hemostatic composite sponge comprising a porous matrix of a biomaterial and a material enhancing the adherence of said sponge to the applied tissue stably associated with at least one surface of said sponge, a method of producing these sponges and their use in hemostasis.
    Type: Application
    Filed: December 16, 2010
    Publication date: August 18, 2011
    Applicants: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Hans Christian Hedrich, Joris Hoefinghoff, Woonza M. Rhee, Atsushi Edward Osawa
  • Patent number: 7871637
    Abstract: Dry cross-linked gelatin compositions are prepared that rapidly re-hydrate to produce gelatin hydrogels suitable as hemostatic sealants. Gelatin is cross-linked in the presence of certain re-hydration aids, such as polyethylene glycol, polyvinylprovidone, and dextran, in order to produce a dry cross-linked gelatin powder. The use of the re-hydration aids has been found to substantially increase the re-hydration rate in the presence of an aqueous re-hydration medium, typically thrombin-containing saline.
    Type: Grant
    Filed: September 21, 2007
    Date of Patent: January 18, 2011
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Zhen Qian, A. Edward Osawa, Cary J. Reich, Donald G. Wallace, Narinder S. Shargill, Felix Vega
  • Publication number: 20090227779
    Abstract: Dry cross-linked gelatin compositions are prepared that rapidly re-hydrate to produce gelatin hydrogels suitable as hemostatic sealants. Gelatin is cross-linked in the presence of certain re-hydration aids, such as polyethylene glycol, polyvinylprovidone, and dextran, in order to produce a dry cross-linked gelatin powder. The use of the re-hydration aids has been found to substantially increase the re-hydration rate in the presence of an aqueous re-hydration medium, typically thrombin-containing saline.
    Type: Application
    Filed: May 19, 2009
    Publication date: September 10, 2009
    Applicants: Baxter International, Inc., Baxter Healthcare S.A.
    Inventors: Zhen Qian, A. Edward Osawa, Cary J. Reich
  • Patent number: 7547446
    Abstract: Dry cross-linked gelatin compositions are prepared that rapidly re-hydrate to produce gelatin hydrogels suitable as hemostatic sealants. Gelatin is cross-linked in the presence of certain re-hydration aids, such as polyethylene glycol, polyvinylprovidone, and dextran, in order to produce a dry cross-linked gelatin powder. The use of the re-hydration aids has been found to substantially increase the re-hydration rate in the presence of an aqueous re-hydration medium, typically thrombin-containing saline.
    Type: Grant
    Filed: June 21, 2007
    Date of Patent: June 16, 2009
    Assignees: Baxter International, Inc., Baxter Healthcare S.A.
    Inventors: Zhen Qian, A. Edward Osawa, Cary J. Reich
  • Publication number: 20080286376
    Abstract: Dry cross-linked gelatin compositions are prepared that rapidly re-hydrate to produce gelatin hydrogels suitable as hemostatic sealants. Gelatin is cross-linked in the presence of certain re-hydration aids, such as polyethylene glycol, polyvinylprovidone, and dextran, in order to produce a dry cross-linked gelatin powder. The use of the re-hydration aids has been found to substantially increase the re-hydration rate in the presence of an aqueous re-hydration medium, typically thrombin-containing saline.
    Type: Application
    Filed: July 21, 2008
    Publication date: November 20, 2008
    Applicant: Fusion Medical Technologies, Inc.
    Inventors: Zhen Qian, A. Edward Osawa, Cary J. Reich
  • Patent number: 7435425
    Abstract: Dry cross-linked gelatin compositions are prepared that rapidly re-hydrate to produce gelatin hydrogels suitable as hemostatic sealants. Gelatin is cross-linked in the presence of certain re-hydration aids, such as polyethylene glycol, polyvinylprovidone, and dextran, in order to produce a dry cross-linked gelatin powder. The use of the re-hydration aids has been found to substantially increase the re-hydration rate in the presence of an aqueous re-hydration medium, typically thrombin-containing saline.
    Type: Grant
    Filed: July 17, 2001
    Date of Patent: October 14, 2008
    Assignees: Baxter International, Inc., Baxter Healthcare S.A.
    Inventors: Zhen Qian, A. Edward Osawa, Cary J. Reich
  • Publication number: 20080187591
    Abstract: Compositions, methods, and kits are provided for sealing applications. Compositions are prepared by combining a first cross-linkable component with a second cross-linkable component to form a porous matrix having interstices, and combining the porous matrix with a hydrogel-forming component to fill at least some of the interstices. The compositions exhibit minimal swelling properties.
    Type: Application
    Filed: August 1, 2007
    Publication date: August 7, 2008
    Applicants: Baxter International, Inc., Baxter Healthcare S.A.
    Inventors: Woonza M. Rhee, Cary J. Reich, A. Edward Osawa, Felix Vega
  • Patent number: 7320962
    Abstract: Dried hemoactive materials comprise both a cross-linked biologically compatible polymer and a non-cross-linked biologically compatible polymer. The cross-linked polymer is selected to form a hydrogel when exposed to blood. The non-cross-linked polymer is chosen to solubilize relatively rapidly when exposed to blood. The non-cross-linked polymer serves as a binder for holding the materials in desired geometries, such as sheets, pellets, plugs, or the like. Usually, the cross-linked polymer will be present in a particulate or fragmented form. The materials are particularly suitable for hemostasis and drug delivery.
    Type: Grant
    Filed: January 20, 2004
    Date of Patent: January 22, 2008
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Cary J. Reich, A. Edward Osawa, Helen Tran
  • Publication number: 20040214770
    Abstract: Dried hemoactive materials comprise both a cross-linked biologically compatible polymer and a non-cross-linked biologically compatible polymer. The cross-linked polymer is selected to form a hydrogel when exposed to blood. The non-cross-linked polymer is chosen to solubilize relatively rapidly when exposed to blood. The non-cross-linked polymer serves as a binder for holding the materials in desired geometries, such as sheets, pellets, plugs, or the like. Usually, the cross-linked polymer will be present in a particulate or fragmented form. The materials are particularly suitable for hemostasis and drug delivery.
    Type: Application
    Filed: January 20, 2004
    Publication date: October 28, 2004
    Applicant: Fusion Medical Technologies, Inc.
    Inventors: Cary J. Reich, A. Edward Osawa, Helen Tran
  • Patent number: 6706690
    Abstract: Dried hemoactive materials comprise both a cross-linked biologically compatible polymer and a non-cross-linked biologically compatible polymer. The cross-linked polymer is selected to form a hydrogel when exposed to blood. The non-cross-linked polymer is chosen to solubilize relatively rapidly when exposed to blood. The non-cross-linked polymer serves as a binder for holding the materials in desired geometries, such as sheets, pellets, plugs, or the like. Usually, the cross-linked polymer will be present in a particulate or fragmented form. The materials are particularly suitable for hemostasis and drug delivery.
    Type: Grant
    Filed: June 10, 1999
    Date of Patent: March 16, 2004
    Assignee: Baxter Healthcare Corporation
    Inventors: Cary J. Reich, A. Edward Osawa, Helen Tran